Implications of the BIA-102474-101 study for review of first-into-human clinical trials

Author:

Eddleston Michael12,Cohen Adam F.3,Webb David J.1

Affiliation:

1. Pharmacology, Toxicology, & Therapeutics, University/BHF Centre for Cardiovascular Science; University of Edinburgh; Edinburgh UK

2. National Poisons Information Service - Edinburgh; Royal Infirmary of Edinburgh; Edinburgh UK

3. Centre for Human Drug Research; Leiden the Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference18 articles.

1. Should we tolerate tolerability as an objective in early drug development?;Cohen;Br J Clin Pharmacol,2007

2. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412;Suntharalingam;N Engl J Med,2006

3. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development;Milton;Toxicol Pathol,2009

4. Expert Scientific Group on Phase One Clinical Trials Final Report 2006

5. Committee for Medical Products for Human Use (CHMP) Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products 2007

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3